Menu
Back to Journals » Hepatic Medicine: Evidence and Research » Volume 13
Reply to Chemical Risk Factors of Primary Liver Cancer: A Short Comment [Response To Letter]
Authors Barsouk A, Thandra KC, Saginala K, Rawla P
Received 6 December 2021
Accepted for publication 21 December 2021
Published 30 December 2021 Volume 2021:13 Pages 145—146
Adam Barsouk,1 Krishna Chaitanya Thandra,2 Kalyan Saginala,3 Prashanth Rawla4
1Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA, 19107, USA; 2Department of Pulmonary and Critical Care Medicine, Sentara Virginia Beach General Hospital, Virginia Beach, VA, USA; 3Plains Regional Medical Group Internal Medicine, Clovis, NM, 88101, USA; 4Department of Medicine, Sovah Health, Martinsville, VA, 24112, USA
Correspondence: Prashanth Rawla
Department of Internal Medicine/Hospitalist, SOVAH Health, 320 Hospital Dr, Martinsville, VA, 24115, USA
Email [email protected]
View the original paper by Mr Barsouk and colleagues
This is in response to the Letter to the Editor
Dear editor
We would like to thank Dr. Laraib Ghanghro for his insightful feedback and for bringing these compounds and their metabolites to our attention. Our understanding of HCC pathogenesis is always changing and contributions like his are essential to keeping physicians, researchers and public health officials informed.
Disclosure
All the authors declare no conflict of interest in this communication.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.